Abstracts tagged "observation"

Abstract Number: 605 • 2018 ACR/ARHP Annual Meeting
Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Klaus Krüger¹, Gerd R. Burmester², Siegfried Wassenberg³, Astrid Thiele⁴ and Matthias H. Thomas⁵, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ³Rheumazentrum Ratingen, Ratingen, Germany, ⁴Krankenhaus St. Josef Wuppertal, Wuppertal, Germany, ⁵Medical Affairs, MSD Sharp & Dohme GmbH, Bünde, Germany
Background/Purpose: Golimumab (GLM) has demonstrated efficacy and safety in patients (pts.) with active RA after treatment with at least one TNFi in a RCT. However,…
Abstract Number: 329 • 2017 ACR/ARHP Annual Meeting
Factors Associated with Worsening Serum Vitamin D Deficiencies in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study
Masanori Nakayama¹, Takefumi Furuya¹, Eisuke Inoue², Eiichi Tanaka¹, Katsunori Ikari¹, Ayako Nakajima¹, Atsuo Taniguchi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Medical Informatics, St. Marianna University School of Medicine, Kawasaki, Japan
Background/Purpose: In 2011, we evaluated serum vitamin D levels in Japanese patients with rheumatoid arthritis (RA) and reported the prevalence of, and factors associated with,…
Abstract Number: 380 • 2017 ACR/ARHP Annual Meeting
Treatment Outcomes of Down Syndrome Arthropathy
Jordan T. Jones¹, Leena Danawala², Nasreen Talib³ and Mara L Becker⁴, ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO, ³General Pediatrics, Children's Mercy Kansas City, Kansas City, MO, ⁴Rheumatology, Children's Mercy Kansas City, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down syndrome arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under…
Abstract Number: 545 • 2017 ACR/ARHP Annual Meeting
Incidence of Infusion Reactions to Intravenous Golimumab: Results from a Prospective, Real-World Community Registry
Rafat Faraawi¹, Andrew Chow², Majed M M Khraishi³, Derek Haaland⁴, Milton F. Baker⁵, Cathy Tkaczyk⁶, Allen J Lehman⁷, Francois Nantel⁶ and Brendan Osborne⁶, ¹McMaster University, Hamilton, ON, Canada, ²Credit Valley Rheumatology, Mississauga, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St John's, NF, Canada, ⁴Rheumatology, Clinical Immunology & Allergy, McMaster University, Barrie, ON, Canada, ⁵VIHA, Victoria, BC, Canada, ⁶Medical Affairs, Janssen Inc., Toronto, ON, Canada, ⁷Janssen Inc., Toronto, ON, Canada
Background/Purpose: Golimumab (GLM) is a monoclonal antibody targeting TNF-alpha, indicated for the treatment of adults with rheumatoid arthritis in combination with methotrexate (MTX). GLM-IV is…
Abstract Number: 802 • 2017 ACR/ARHP Annual Meeting
Sensorineural Hearing Loss in Takayasu’s Arteritis
Ugur Kimyon¹, Sinem Nihal Esatoglu¹, Ebru Kara², Ahmet Atas², Elif Emel Gunay², Emine Deniz Gozen², Emin Karaman², Vedat Hamuryudan¹, Hasan Yazici¹ and Emire Seyahi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University, Cerrahpasa Medical Faculty, Department of Otorhinolaryngology, Istanbul, Turkey
Background/Purpose: Sensorineural hearing loss has been reported to be increased in several chronic autoimmune and non-autoimmune diseases such as systemic lupus erythematosus (SLE), progressive systemic…
Abstract Number: 2448 • 2017 ACR/ARHP Annual Meeting
Increased Cumulative Exposure to Tumor Necrosis Factor Inhibitors Reduces Radiographic Progression in US Veterans with Rheumatoid Arthritis in Real World Clinical Practice
Grant Cannon¹, Alan R. Erickson², Chia-Chen Teng, MS¹, Tina Huynh¹, Sally W. Wade³, Bradley S. Stolshek⁴, David Collier⁵, Alex Mutebi⁶ and Brian C. Sauer, PhD¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Wade Outcomes Research and Consulting, Salt Lake City, UT, ⁴Amgen, Inc., Thousand Oaks, CA, ⁵Amgen Inc., Thousand Oaks, CA, ⁶Global Health Economics, Amgen Inc., Thousand Oaks, CA
Background/Purpose: While tumor necrosis factor inhibitors (TNFi) have been proven to reduce progression of structural joint damage in rheumatoid arthritis (RA) in randomized clinical…
Abstract Number: 2486 • 2017 ACR/ARHP Annual Meeting
Rituximab Is an Attractive Proposition to Treat Difficult Active RA in Indian (Asia) Patients: Initial Results of a Non Commercial Initiative Using an Initial Regimen of Two 500 Mg Infusions (fortnightly) and a Third 500 Mg Infusion at 6 Weeks in Case of Inadequate Response(ACR 50)
Arvind Chopra¹, KIRAN ADAM², NACHIKET KULKARNI³, Anuradha Venugopalan⁴, Toktam Kainifard⁵ and Manjit Saluja⁶, ¹Center for Rheumatic Diseases, Pune, India, Pune, India, ²Rheumatology physician, PUNE, India, ³MD, DNB, PUNE, India, ⁴Rheumatology, R & D, Lab, Center for Rheumatic Diseases, Pune, India, ⁵Rheumatology, Consultant research and Dietitian, Pune, India, ⁶Rheumatology, Co-ordinator Research, Pune, India
Background/Purpose: Considering the huge burden of RA in India, the use of biologic DMARDs is miniscule. The major deterrents are cost, poor awareness and few…
Abstract Number: 2861 • 2017 ACR/ARHP Annual Meeting
Treat-to-Target in Rheumatoid Arthritis: What Level of Treatment Response Is Necessary By 3 Months in Order to Achieve the Treatment Target By 6 Months? Results from the Real Life NOR-DMARD Study
Vibeke Norvang¹, Inge C Olsen², Joseph Sexton¹, Eirik K Kristianslund¹, Till Uhlig¹, Tore Kvien³, Daniel Aletaha⁴, Josef S. Smolen⁴ and Espen A. Haavardsholm¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria
Background/Purpose : In a treat-to-target strategy in rheumatoid arthritis (RA) treatment adoptions are recommended in case of poor improvement in disease activity 3 months after…
Abstract Number: 2893 • 2017 ACR/ARHP Annual Meeting
The Use of Natural Language Processing to Identify, Retrieve, Report, and Correct Observational Data on US Veterans Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Grant Cannon¹, Jorge Rojas¹, Neill Bell², Andreas Reimold³, Ted R. Mikuls⁴, Namrata Singh⁵, Gail S. Kerr⁶, Pascale Schwab⁷, Jennifer Barton⁷, Liron Caplan⁸, Joshua Baker⁹, Angelo L. Gaffo¹⁰, J. Steuart Richards¹¹, Deana Lazaro¹², Vikas Majithia¹³ and Brian Sauer¹, ¹Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ²Salt Lake City VA Medical Center and University of Utah, Dallas VA Medical Center, Dallas, TX, ³Dallas VA Medical Center and University of Texas Southwestern, Dallas, TX, ⁴VA Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, ⁵VA Nebraska-Western Iowa Health Care System and University of Iowa, Omaha, IA, ⁶Washington DC VA Medical Center, Georgetown and Howard University Hospitals, Washington, DC, ⁷Portland VA Medical Center and University of Oregon, Portland, OR, ⁸Denver VA Medical Center and Univerity of Colorado, Denver, CO, ⁹Philadelphia VA Medical Center and University of Pennsylvania, Philadelphia, PR, ¹⁰Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, ¹¹Pittsburgh VA Medical Center and University Of Pittsburgh, Pittsburgh, PA, ¹²Brooklyn VA Medical Center and SUNY Downstate, Brooklyn, NY, ¹³Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: The Veterans Affairs (VA) Rheumatoid Arthritis (RA) (VARA) registry is an observational cohort study at 12 VA medical centers that prospectively collects clinical…
Abstract Number: 114 • 2017 Pediatric Rheumatology Symposium
Clinical Features and Treatment Outcomes in Down’s Arthropathy
Jordan T. Jones¹ and Leena Danawala², ¹Rheumatology Division, Children's Mercy Kansas City, Kansas City, MO, ²University of Missouri-Kansas City School of Medicine, Kansas City, MO
Background/Purpose: Crude prevalence estimates indicate Down’s Arthropathy (DA) is 3-8 times more common than juvenile idiopathic arthritis (JIA), however, DA is still largely under recognized…
Abstract Number: 2231 • 2016 ACR/ARHP Annual Meeting
Change in Health Care Utilization after Etanercept Initiation in Patients with Rheumatoid Arthritis
Neil Accortt¹, Jennifer Schenfeld^2,3, Eunice Chang⁴, Elya Papoyan⁴ and Michael S. Broder⁴, ¹Center for Observational Research, Amgen, Inc, Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA, ³Amgen Inc., Thousand Oaks, CA, ⁴Partnership for Health Analytic Research, LLC, Beverly Hills, CA
Background/Purpose: Patients with rheumatoid arthritis (RA) have higher healthcare utilization (HCU) and costs than patients without RA1. Evidence is mixed as to the impact of…
Abstract Number: 1879 • 2015 ACR/ARHP Annual Meeting
Immunosuppressive “Routine”� Treatment of SSc Patients with Limited Cutaneous Involvement and Interstitial Lung Disease
Dörte Huscher¹, Sabine Adler², Elise Siegert³, Giuseppina Abignano⁴, Yannick Allanore⁵, Jerome Avouac⁶, Kerstin Becker⁷, Laszlo Czirjak^8,9, Francesco Del Galdo¹⁰, Christopher P. Denton¹¹, Oliver Distler¹², Ivan Foeldvari¹³, Beata Garay-Toth¹⁴, Serena Guiducci¹⁵, Veronika K. Jaeger¹⁶, Veronika Lóránd⁹, Marco Matucci-Cerinic¹⁷, Britta Maurer¹⁸, Ulf Müller-Ladner¹⁹, Svetlana I. Nihtyanova²⁰, Ingo H. Tarner²¹, Gabriele Valentini²², Serena Vettori²³, Ulrich A. Walker²⁴ and Gabriela Riemekasten²⁵, ¹Charité-University Hospital and German Rheumatism Research Centre, Berlin, Germany, ²Rheumatology, Immunology, Allergology, University Hospital Bern, Bern, Switzerland, ³Rheumatology and Clinical Immunology, Charité – University Hospital, Berlin, Berlin, Germany, ⁴Clinical and Experimental Medicine, Second University of Naples, Napoli, Italy, ⁵Department of Rheumatology A, Paris Descartes University, Cochin Hospital, Paris, France, ⁶Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁷Rheumatology and Clinical Immunology, Charité University Hospital, Berlin, Germany, ⁸Rheumatology, Pecs, Hungary, ⁹Rheumatology and Immunology Medical School, University of Pécs, Pécs, Hungary, ¹⁰Scleroderma Group, Leeds Institute of Molecular Medicine, Leeds, United Kingdom, ¹¹Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ¹²Department of Rheumatology, Research of Systemic Autoimmune Diseases, University Hospital Zurich, Zurich, Switzerland, ¹³Hamburger Zentrum für Kinder-und Jugendrheumatologie, Hamburg, Germany, ¹⁴FESCA, Budapest, Hungary, ¹⁵Rheumatology, University of Florence, Florence, Italy, ¹⁶Department of Rheumatology, University Hospital Basel, Basel, Switzerland, ¹⁷Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, ¹⁸r, University Hospital Zurich, Zurich, Switzerland, ¹⁹Internal Medicine and Rheumatology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²⁰Rheumatology, UCL Division of Medicine, London, United Kingdom, ²¹Rheumatology and Clinical Immunology, Justus-Liebig-University of Giessen, Kerckhoff-Klinik, Bad Nauheim, Germany, ²²Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²³Department of Internal and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²⁴Rheumatology, Systemic Sclerosis, Basel, Switzerland, ²⁵Clinic of Rheumatology, University of Luebeck, Lübeck, Germany
Background/Purpose: Interstitial lung disease (ILD) represents one of the most frequent causes of death in systemic sclerosis (SSc) patients. Yet, there are no approved drugs…
Abstract Number: 2172 • 2015 ACR/ARHP Annual Meeting
Distribution of Clinical Osteoarthritis and Associations to Health-Related Quality of Life in a Population-Based Osteoarthritis Cohort
Guro Økelsrud Lombnæs¹, Karin Magnusson² and Kåre Birger Hagen¹, ¹National Advisory Unit on Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, National Advisory Unit on Rehabilitation in Rheumatology, Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: Osteoarthritis (OA) is a major cause of musculoskeletal pain and disability, and is commonly reported to impair health-related quality of life (HRQoL). We aimed…
Abstract Number: 2666 • 2015 ACR/ARHP Annual Meeting
Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort
Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Yoko Shimizu, Naoki Sugimoto, Kumi Shidara, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient-reported outcomes are recognized as important for evaluating the disease status of rheumatoid arthritis (RA). The EuroQol 5-dimensional descriptive system (EQ-5D) has been used…
Abstract Number: 455 • 2015 ACR/ARHP Annual Meeting
Predictors of Real-World Treatment Sustainability in RA Patients Treated with Abatacept in Canada: Implications for Routine Care
Janet E. Pope¹, Emmanouil Rampakakis² and John S. Sampalis³, ¹University of Western Ontario, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Clinical Research, JSS Medical Research, Westmount, QC, Canada
Background/Purpose: Treatment sustainability can measure drug effectiveness and encompasses drug effectiveness, safety, and compliance. Recent data suggest that differences in retention may exist between biologic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].